Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590605 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL4251359 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL4027475 | 1.00 | BCHE (0.79) | BCHEKMT2AACHEKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28933519 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Bromide SCHEMBL5898942 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Bromide SCHEMBL5898925 | 0.99 | BCHE (0.77) | BCHEKMT2AACHEKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28933498 | 0.92 | KDM4E (0.73) | BCHEKMT2AACHEKDM4EMAPT | |
| SCHEMBL28933497 | 0.90 | KDM4E (0.78) | BCHEKMT2AACHEKDM4EMAPT | |
| Tetrahydropapaverine SCHEMBL251076 | 0.89 | BCHE (0.79) | BCHEKDM4EMAPTPKM | |
| Tetrahydropapaverine SCHEMBL6398843 | 0.89 | BCHE (0.79) | BCHEKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | claimed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | claimed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | claimed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | claimed |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2009-02-05 | — | — | US | disclosed |
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | YUN-CHOI HYE-SOOK | 2006-03-16 | — | — | US | disclosed |
| EP-1507764-A4 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1507764-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | Yun-Choi, Hye-Sook (KR) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003095426-A1 | NOVEL ENANTIOMERS OF TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | YUN-CHOI HYE-SOOK (KR) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058346-A1 | Novel enantiomers of etrahydroisoquinoline derivatives and theirpharmaceutically acceptable salts, their preparations and pharmaceutical compositions | TBXA2R, NOS2, TBXAS1 | BCHE 1219/4885KMT2A 3931/4885ACHE 1102/4885 |
| US-20090036679-A1 | METHOD FOR RESOLVING ENANTIOMERS FROM RACEMIC MIXTURE HAVING CHIRAL CARBON IN ALPHA POSITION OF NITROGEN | SRR, NPEPPS, DNPEP | BCHE 11/4885KMT2A 4063/4885ACHE 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.